iRegene Therapeutics Advances Neurodegenerative Disease Treatments with New Cell Therapy Candidates

iRegene Therapeutics Expands Neuroscience Programs with Clinical Advances in Neurodegenerative Diseases

CHENGDU, China, Feb. 23, 2026 — iRegene Therapeutics significantly progresses its global cell therapy initiative focused on neurodegenerative diseases, specifically highlighting advancements in two novel candidates aimed at treating Parkinson's disease and Multiple System Atrophy (MSA). Recently, the company first administers its cell therapy NouvNeu001 to a U.S. patient in an open-label Phase IIa clinical trial at Weill Cornell Medical Center. This innovative treatment, which utilizes dopaminergic progenitor cells derived from induced pluripotent stem cells (iPSCs), employs a highly specialized delivery method via stereotactic neurosurgery, targeting the bilateral putamen. This marks a vital step towards not only addressing the symptoms of Parkinson's disease but also challenging the mechanisms behind it.

In parallel, iRegene enrolls its first patient in a randomized controlled trial of NouvNeu004 for MSA at Beijing Tiantan Hospital, led by Principal Investigator Professor Yilong Wang. NouvNeu004 adopts a unique dual approach to tackle the effects of MSA, offering neurotrophic support while simultaneously promoting neural reconstruction. These initiatives build upon encouraging Phase I data, positioning iRegene as a frontrunner in delivering effective and advanced therapeutics for these debilitating conditions, particularly as they experience rapid disease progression.

The U.S. Food and Drug Administration's decision to grant rapid pathway designations, including Fast Track Designation and Regenerative Medicine Advanced Therapy designation, facilitates NouvNeu001’s transition into Phase II. This strategy is designed to enhance the treatment's efficacy while employing a “single dose, sustained benefit” model intended to replace the lost neurons and potentially reshape disease trajectories. Meanwhile, the expedited approvals from China’s NMPA for integrated trial phases further underlines the urgency and necessity of international collaboration in clinical research. The novel "AI + Chemical Induction" platform, which underpins both therapies, helps streamline the process from candidate selection to scalable manufacturing, enhancing patient enrollment across various jurisdictions and fostering a more efficient regulatory engagement process.

In related news, iRegene also anticipates that both of these programs will provide harmonized cross-border datasets, which are crucial for understanding treatment impacts in diverse populations. This regulatory momentum not only propels the company towards crucial mid-stage efficacy evaluations but aims to pave the way for potential pivotal trials that could change the landscape of neurodegenerative treatment options significantly. The intersection of advanced technology and cell therapy continues to cement iRegene's position in the dynamic field of neurobiology and regenerative medicine.